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Abstract
The obligate intracellular developmental cycle of Chlamydia trachomatis presents signifi-
cant challenges in defining its proteome. In this study we have applied quantitative proteo-
mics to both the intracellular reticulate body (RB) and the extracellular elementary body
(EB) from C. trachomatis. We used C. trachomatis L2 as a model chlamydial isolate for our
study since it has a high infectivity:particle ratio and there is an excellent quality genome
sequence. EBs and RBs (>99% pure) were quantified by chromosomal and plasmid copy
number using PCR, from which the concentrations of chlamydial proteins per bacterial cell/
genome were determined. RBs harvested at 15h post infection (PI) were purified by three
successive rounds of gradient centrifugation. This is the earliest possible time to obtain puri-
fied RBs, free from host cell components in quantity, within the constraints of the technol-
ogy. EBs were purified at 48h PI. We then used two-dimensional reverse phase UPLC to
fractionate RB or EB peptides before mass spectroscopic analysis, providing absolute
amount estimates of chlamydial proteins. The ability to express the data as molecules per
cell gave ranking in both abundance and energy requirements for synthesis, allowing mean-
ingful identification of rate-limiting components. The study assigned 562 proteins with high
confidence and provided absolute estimates of protein concentration for 489 proteins. Inter-
estingly, the data showed an increase in TTS capacity at 15h PI. Most of the enzymes
involved in peptidoglycan biosynthesis were detected along with high levels of muramidase
(in EBs) suggesting breakdown of peptidoglycan occurs in the non-dividing form of the
microorganism. All the genome-encoded enzymes for glycolysis, pentose phosphate path-
way and tricarboxylic acid cycle were identified and quantified; these data supported the
observation that the EB is metabolically active. The availability of detailed, accurate quanti-
tative proteomic data will be invaluable for investigations into gene regulation and function.
PLOS ONE | DOI:10.1371/journal.pone.0149011 February 12, 2016 1 / 17
OPEN ACCESS
Citation: Skipp PJS, Hughes C, McKenna T,
Edwards R, Langridge J, Thomson NR, et al. (2016)
Quantitative Proteomics of the Infectious and
Replicative Forms of Chlamydia trachomatis. PLoS
ONE 11(2): e0149011. doi:10.1371/journal.
pone.0149011
Editor: Thomas Rudel, University of Würzburg,
GERMANY
Received: July 16, 2015
Accepted: January 26, 2016
Published: February 12, 2016
Copyright: © 2016 Skipp et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the manuscript and its supporting information
files. The mass spectrometry proteomics data have
been deposited to the ProteomeXchange Consortium
via the PRIDE partner repository with the dataset
identifier PXD003025.
Funding: This study was supported by a grant from
the Wellcome Trust (#057347). This funder had no
role in study design, data collection and analysis,
decision to publish, or preparation of manuscript.
Waters Corporation provided support in the form of
salaries for authors C.H., T.M. and J.L. These authors
Introduction
Chlamydia trachomatis is the commonest cause of bacterial sexually transmitted infection in
Europe and the USA [1]. C. trachomatis genital tract infections are frequently asymptomatic
and thus if treatment is not sought the infection is spread silently [2, 3]. The highest rates of
infection are amongst the 16–24 year old age group [4, 5]. Symptomless, and therefore
untreated, C. trachomatis infections can give rise to severe, long term sequelae. In women,
complications of chronic chlamydial infections are pelvic inflammatory disease, tubal infertility
and ectopic pregnancy [6, 7]. C. trachomatis infections are treatable with antibiotics, although
treatment failures appear common [8]. The cases of C. trachomatis continue to rise despite sig-
nificant efforts to control the spread of infection. The patterns of chlamydial infection have
shown some significant increasing trends in recent years with the emergence of a new variant
strain in Sweden and an epidemic of lymphogranuloma venereum in the MSM population[9,
10]. Thus understanding the structure and function of the infectious (elementary body or EB)
and dividing (reticulate body or RB) forms of C. trachomatis is of fundamental importance to
developing better treatments and new diagnostic procedures.
C. trachomatis is an obligate intracellular pathogen; eukaryotic host cell infection begins
when the extracellular infectious form of the microorganism, the EB binds to a susceptible cell
[11]. The bacteria are taken up within a cytoplasmic vesicle, which is rapidly subverted to
become a protected, membrane-surrounded environment known as an inclusion within which
the chlamydia can grow and divide. The first steps in this process involve the re-organisation
of the EB into a RB within an inclusion, and takes some 8–18 hours depending on the host cell
and chlamydial strain. RBs divide by binary fission and the first-formed RB will undergo seven
to eight binary fissions before the progeny re-condense to form EBs, which are subsequently
released by host cell lysis [12]. A productive round of chlamydial infection, known as a devel-
opmental cycle, concludes with the release of some 200–500 infectious progeny per inclusion,
as is the case with the model strain of C.trachomatis L2 used in this study to infect BGMK cells
[13]
A key challenge in chlamydial biology is to define the differences at the molecular level
between EBs and RBs. These have involved either transcriptional [14, 15] and proteomic
approaches[16, 17]. It is difficult to infer levels of protein expression and stages of the develop-
mental cycle from transcriptional data alone due to the influence of post-transcription regula-
tory processes, thus we have proposed that evaluation of the developmental cycle should be
standardised by measuring chromosomal and plasmid replication rates [12]. A further con-
founding factor is defining what constitutes an RB, especially as the co-ordination of the devel-
opmental cycle rapidly looses synchrony once RB division begins [14]. In this respect, we have
purified RBs from just before chromosomal replication, and hence RB division begins, these
are the first-formed RBs. In addition, we have minimised the possibility of multiply infected
and hence metabolically stressed host cells by a using a multiplicity of infection (MOI = 3).
Recently, it has been shown that EBs are metabolically active, this is a paradigm shift in our
understanding of the basic physiology of Chlamydia [18]. The accurate direct measurement of
protein levels and comparison between defined populations of EBs and RBs, extracted directly
from their natural environment, will provide new insights into the active processes within EBs
and RBs.
We have employed two-dimensional reverse phase UPLC to fractionate chlamydial
peptides prior to MSE analysis providing absolute amount estimates of the identified proteins,
offering a number of significant advantages over relative quantification. For example, by
expressing data in terms of molecules per cell, proteins can be ranked in terms of their abun-
dance and measures of the amount of energy invested in their synthesis calculated, facilitating
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the identification of potentially rate-limiting components. Such data is a prerequisite for build-
ing quantitative predictive models of cellular behavior and assists inter-study comparisons as
each measurement is independent and does not have to be linked to an equivalent one in a ref-
erence sample.
Using an 11-step high-pH, low pH, two stage fractionation, we have achieved extended pro-
teome and protein coverage compared to other reported studies. The data reveal hitherto
uncharacterized proteins to be amongst the most abundant components of both the EB and RB
forms of C. trachomatis, and indicate where C. trachomatis invests its energy in protein synthe-
sis. They also pinpoint proteins with exquisite accuracy that are differentially expressed
between EBs and first-formed RBs and hence associated with differences in metabolism, infec-
tivity and survival between these two forms of the pathogen. In particular, it has allowed quan-
titative characterisation of those proteins involved in energy metabolism providing further
information on the metabolic activity profiles within chlamydia during the developmental
cycle.
Materials and Methods
Chlamydia and cells
C. trachomatis L2/434/Bu (VR902B) was originally obtained from the ATCC. This isolate was
plaqued purified three times and verified by sequence analysis of the ompA gene as previously
described [16]. C. trachomatis L2 434/Bu was grown in Buffalo green monkey cells (BGMK) in
DMEM supplemented with 10% foetal calf serum containing cycloheximide at 1μg/ml [12].
Stocks of C. trachomatis were prepared as described previously [19]. The infectivity of EB prep-
arations was titred by serial dilution in 96-well trays. Briefly, mature inclusions were stained
using an in-house monoclonal genus-specific antibody that recognizes the chlamydial LPS, the
bound monoclonal antibody was detected with a rabbit polyclonal IgG conjugated to β-galacto-
sidase. Specific details of the procedure for staining and counting inclusions are as described
[20]. C. trachomatis and BGMK cells were routinely tested for mycoplasma contamination by
fluorescence microscopy using Hoechst No. 33258 staining and using VenorGem1Myco-
plasma PCR Detection Kit (MinervaBiolabs, Berlin, Germany).
Purification of EBs and RBs and quantification of EBs
For large scale purification of EBs and RBs eighteen T-175 tissue culture flasks were infected
with a carefully titred inoculum of EBs (moi = 3.0) The earliest stage RBs were purified at 15hrs
post infection, some 3–5 hrs before inclusions become visible (in this system) by phase contrast
microscopy [12]. EBs were harvested at 48hrs post infection when the proportion of mature
EBs were at their maximum and before inclusions started to lyse [12]. Chlamydia–infected
BGMK cells were detached from the plastic flasks with PBS containing 0.125% trypsin/0.02%
EDTA and then pelleted in DMEM containing 10% FCS at 3,000 x g for 10 mins. The chla-
mydia-infected BGMK cell pellet was suspended in PBS:H2O (1:10), the cells were lysed and
EBs and RBs released using a Dounce homogenizer. The cell debris was sedimented at 250 x g
for 5 mins and the supernatant retained and mixed with an equal volume of PBS. RBs and EBs
were then purified through two cycles of density gradient purification as previously described
in detail [16]. Finally, the material was purified on discontinuous urografin gradients with RBs
banding at the 34/44% interface and EBs banded at 44/54% interface. RB and EB fractions were
collected by sedimentation at 3500 x g in a Beckman 55.2 rotor as previously described [16].
These highly purified EBs and RBs were re-suspended in PBS and stored in aliquots at -80°C.
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Genome quantification of RBs and EBs by real-time qPCR
A single copy of the omcB gene is located on the C.trachomatis L2/434/Bu chromosome [19].
The absolute number of genomes in the highly purified RB and EB preparations was accurately
determined by performing 50-exonuclease (TaqMan) assays with unlabelled primers and car-
boxyfluorescein/carboxytetramethylrhodamine (FAM/TAMRA) dual-labelled probes based on
the omcB gene as previously described [21]. Briefly, DNA was extracted from 5ul of purified
EBs/RBs using the protocol described in Salim et al 2008 [22]. 5ul of this DNA preparation was
added to a 20 μl reaction mixture containing forward primer (300 nM), reverse primer (300
nM), probe (100 nM) and TaqMan Universal PCR Master Mix (Applied Biosystems). Real-
time PCR cycles were performed in an ABI PRISM 7700 Sequence Detection System (Applied
Biosystems) according to the manufacturer’s instructions. This allowed the concentration of
EB and RB genomes to be determined per ml of pellet suspension, providing a suitable method
of normalizing the samples.
Expression of CTL0847 in E.coli, polyclonal sera and immunoblotting
The coding sequence for gene CTL 0847 from C.trachomatis L2/434/Bu was cloned and
expressed using the Xpress™ system (Invitrogen life technologies) which allows expression of a
recombinant protein fused at the N–terminual to a six-histidine tag, facilitating purification.
CTL0847 specific primer pair, CTL0847_BamHI_F:5’-GGTGGTGGATCCATGACGAC
GAAACCCAAAAC-3’ and CTL0847_HindIII_R:5’-GGTGGTAAGCTTTTACACAGA
TTTCGTTAATTC-3’ (engineered restriction sites, (BamH1 and Hind III) are shown in bold,
preceding the complementary recognition sequence) were used to amplify the CTL 0847 gene
using C.trachomatis L2/434/Bu genome as template in a PCR reaction containing Phusion
Flash High-Fidelity PCR Master Mix (Thermo Scientific)over 35 cycles of 98°C for 2s, 56°C for
5 s and 72°C for 30 s. The 552 bp amplicons were gel-purified, cleaved with BamH1 and Hind
III and cloned into pRSETA (Invitrogen). Soluble purified CTL0847 protein, purified using the
Xpress system (Invitrogen) according to the manufacturer’s instructions was used to raise a
mono specific polyclonal mouse serum as previously described. SDS PAGE and immunoblot-
ting was performed as previously described [23].
Sample preparation for MS
Highly purified EBs and RBs were pelleted by centrifugation at 13,000 x g for 10 min at 4°C
and the supernatant discarded. 200 μL of 0.5M triethylammonium bicarbonate (Sigma Aldrich,
Poole, Dorset.) containing 10 mMDTT and 0.1% SDS were added to the cells and incubated
on ice for 2 h. Bacterial cells were mechanically disrupted using a FastPrep system (Savant) in
combination with Lysing Matrix D ceramic beads (Q-Biogene) for 6 cycles, followed each time
by incubation on ice. The cell lysate was further processed using 3 cycles of sonication using a
Misonix sonicator and microprobe, followed by 1 min incubations on ice. The bacterial lysates
were centrifuged at 13,000 x g for 10 min to remove cell debris. Protein concentration was
determined using the Bradford protein assay (BioRad Laboratories, Hercules, CA, USA). Sam-
ples were flash frozen and stored at -80°C until ready for use
Preparation of protein digests
Total protein lysates of EB and RB preparations were reduced for 1 h at 56°C using 50 mM
tris-(2-carboxyethyl) phosphine, alkylated with 200 mMmethyl methane-thiosulfonate for
10 min at RT and proteolytically digested using trypsin by the addition of 1:25 (w/w) trypsin-
to-protein and incubating overnight at 37°C. 100 μg of the peptide lysates were lyophilized in
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vacuo and re-suspended in 100 mM ammonium formate containing the internal reference pro-
tein alcohol dehydrogenase (ADH) at a final concentration of 20 fmol/μl.
2D-RPLC-MSE
Two-dimensional separations were performed using a nanoAcquity 2D UPLC system
(Waters). For the first dimension separation, 4.5 μl of the prepared protein lysates containing
90 fmol of an ADH digest were injected onto a 5μm Xbridge BEH130 C18, 300μm ID x 50mm
(Waters) column equilibrated in 20 mM ammonium formate, pH 10 (buffer A). The first
dimension separation was achieved by increasing the concentration of acetonitrile (buffer B)
in 11 steps consisting of 8.2%, 11.7%, 13%, 14.5%, 15.9%, 17.4%, 18.9%, 20.8%, 23.6%, 45%,
65%. At each step the programmed percentage composition was held for 1 min at a flow rate of
2μl/min and the eluent diluted by buffer C (H2O + 0.1% formic acid) from the second dimen-
sion pump at a flow rate of 20ul/min, effectively diluting the ammonium formate and acetoni-
trile, allowing trapping of the eluting peptides onto a Symmetry C18, 180μm x 20mm trapping
cartridge (Waters). After 15 min washing of the trap column, peptides were separated using an
in-line second dimension analytical separation performed on a 75μm ID x 200mm,1.7μm
BEH130 C18, column (Waters) using a linear gradient of 5 to 40% B (buffer A = 0.1% formic
acid in water, buffer B = 0.1% formic acid in acetonitrile) over 90 min with a wash to 85% B at
a flow rate of 300 nl/min. All separations were automated and performed on-line to the mass
spectrometer.
All mass spectrometry was performed using a Synapt Q-Tof mass spectrometer fitted with a
nanolockspray source operating in MSe mode (Waters, Manchester, UK). Data was acquired
from 50 to 1990m/z using alternate low and high collision energy (CE) scans. Low CE was 5V
(Trap), 4V (Transfer) and elevated was 12-35V ramp (Trap), 10V (transfer). The lock mass
Glu-fibrinopeptide, (M+2H)+2,m/z = 785.8426) was infused at a concentration of 100 fmol/μl
at 250 nl/min and data acquired every 60 seconds.
Data processing
ProteinLynx Global Server 2.3 was used to process each raw data file, to generate reduced
charge state and deisotoped precursor and associated product ion mass lists. Each processed
file was searched against a protein translation of the C. trachomatis L2/434/Bu (897 entries,
Jan, 2008) and Human genome sequence (Mar, 2009) including the L2 plasmid sequence (8
entries, Jan, 2008) [19] and the internal standard alcohol dehydrogenase (Saccharomyces cere-
visiae) using the PLGS database search algorithm IDENTITYE (Waters). Search parameters
were as follows: Precursor and product ion tolerance were 10 ppm and 15 ppm respectively.
Data were also searched against a combined database of the C. trachomatis L2/434/BU genome
and all Uniprot entries available for the human proteome. Peptides that were homologous
between C. trachomatis and human were removed from the dataset using an in-house script. A
false positive rate of 4% was applied. Data was further filtered for protein quantitation by only
considering proteins that were identified in at least two replicates of the same developmental
form. By using the replication of protein assignments across different injections, the false posi-
tive rate is minimized, since chemical noise is random in nature and does not end to replicate
across injections [24]
Data normalisation
Normalisation to obtain estimates of absolute concentration were calculated using the ‘Top3’
approach implemented within the software IDENTITYE [25]. In brief, the average intensity of
the ‘Top3’ most abundant peptides of the internal standard alcohol dehydrogenase was used to
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calculate a universal response factor (counts/ mol of protein). This response factor was applied
to the average intensity of the ‘Top3’ most abundant peptides from all other assigned proteins
to provide estimates of their absolute concentration on column. Each sample was normalized
on a per bacterium basis. Based upon the assumption that one omcB gene (calculated as
described above) is equivalent to one genome, and that one genome is equivalent to a single
bacterium, the number of bacterial cells equivalent to the amount of digested protein lysate
injected on column was determined and the number of molecules per bacterium calculated.
Energy expended during protein synthesis
To a first approximation, the energy expended in synthesizing a specific protein within a cell
was calculated as follows. 60 kcal/mol are required to extend a nascent polypeptide chain by a
single amino acid [26]. This energy expenditure arises from (i) the synthesis of a codon encod-
ing a specific amino acid, (ii) the charging of the tRNA by its synthetase with the cognate
amino acid, and (iii) the incorporation of the amino acid into the nascent polypeptide chain.
The required energy for this process is generated from the hydrolysis of 10 energy-rich bonds
in the form of either ATP or GTP, each with an energy content of about ΔG = -6 kcal/mol.
Therefore, the number of constituent amino acids of each protein obtained from the UniProt
protein database was used to calculate the energy required to synthesise one molecule of each
specific protein identified. Using the number of molecules per bacterium calculated for each
protein, showing an increased concentration in EBs, the total amount of energy invested in
synthesising a specific protein per bacterium was calculated.
Results and Discussion
C. trachomatis L2 is our model system of choice for studying proteomics, genome analysis and
chlamydial transformation. This bacterial isolate belongs to the lymphogranuloma ‘biovar’
from which strains cause invasive disease and they are thus not typical of urogenital chlamydia
which are confined to the mucosal surfaces, but LGV isolates are ideal for laboratory analyses
of basic biology in cell culture as they are fast growing and have a high particle to infectivity
ratio. The specific strain we chose for this study is C. trachomatis L2/4343/Bu which has a high
quality matching genome sequence [19]. It was subject to three plaque purifications to ensure
clonality and all subsequent passages were subject to rigorous testing for mycoplasma. In our
work we used BGMK cells as the eukaryotic host since these cells grow very evenly and have a
distinctive morphology that allows ready identification of inclusions by phase contrast micros-
copy. The BGMK cells are clonal, easily infected and centrifugation is not required to initiate
infection by C. trachomatis L2, which means the process is efficient. The bacteria are endocy-
tosed into a cytoplasmic vesicle which is then subverted by microbial processes to become an
‘inclusion’. In BGMK cells the process of conversion from EB to dividing RB for C. trachomatis
L2 occurs within inclusions and takes some 18hrs, inclusions are just visible by phase contrast
microscopy, after this time the RBs rapidly divide by binary fission [12]. We have carefully cali-
brated this process and found that the earliest time it is possible to harvest and purify an
homogenous population of RBs, is 15hrs post infection. This is just prior to the commence-
ment of both bacterial cell division and chromosomal replication, our experimental design is
shown in Fig 1A. Since asynchrony arises in the developmental cycle soon after this point, it is
only possible to purify early RBs and mature EBs as distinct bacterial populations, within the
constraints of the current technology. RBs and EBs were extracted from infected cells as previ-
ously described and then purified through two cycles of density gradient centrifugation fol-
lowed by overlaying onto a discontinuous gradient. The purity of EBs and RBs was assessed by
TEM as previously described [16, 27] and preparations were>99% pure for RBs and EBs.
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Yields of RBs were low at 2 mg for 18 x T175 flasks at moi of 3.0 when 95% of the cells are
infected, we found it was not possible to obtain reasonable yields at lower moi, and above this
threshold especially at moi = 10, EBs were cytotoxic in our experimental system [12].
Proteome coverage
Tryptic peptides prepared from EB and RB samples harvested at 15 h and 48 h post-infection,
respectively, were analysed using a two-dimensional reverse phase UPLC-MSE strategy (Fig
1B). Two biological replicates were prepared for each sample (2 x purified EB, 2 x purified RB).
Two complete protein quantification profiles were obtained for each biological sample to give
the identity and an estimate of the absolute amount of each protein within each sample. The
mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium
[27] via the PRIDE partner repository with the dataset identifier PXD003025. Fig 2 highlights
the comprehensive peptide coverage obtained for RBs and EBs across the chlamydial genome.
Protein identification by this method was supported by an average of 46 peptides per protein (a
minimum of 64% sequence coverage, (S1D–S1K Fig) while comparison of absolute protein
estimates between technical replicates for protein lysates indicated an R2 value of 0.961 for EBs
(S1A Fig) and 0.808 for RBs (S1B Fig), with mean % coefficients of variation between technical
Fig 1. TheC. trachomatis L2 developmental cycle (A) and the experimental workflow for the analysis of highly purifiedC. trachomatis L2 EBs and RBs using
2D-RP-RP-LC-MSE label-free technology (B).
doi:10.1371/journal.pone.0149011.g001
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replicates, ranging from 12.9 to 16.9% across the dataset. Altogether, 562 proteins were identi-
fied and estimates of absolute amounts were collected for 489 proteins (S1 Table), representing
Fig 2. Circular chlamydial genomewith peptide data mapped to CDSs.Circular representation of the C. trachomatis L2 chromosome and the mapping of
peptides assigned from both EBs and RBs to their corresponding CDS. The outer scale shows the size in bp. The outer circle shows the positions of the CDS
in a clockwise direction. The green and red circles indicate the CDSs of the peptides assigned in RBs and EBs, respectively. Using the published gene
predictions for C. trachomatis strains UW-3 and Har-3, the strain L2 CDSs have been colour coded depending on whether the are: (blue) predicted and intact
in all isolates; (pink) predicted and intact in L2 and UW-3; (green) predicted and intact in L2 and Har-13; (orange) defunct in L2, predicted and intact in Har-13
and UW-3; (red) unique to L2; (brown) defunct in all isolates. The region spanning the plasticity zone (PZ) is indicated.
doi:10.1371/journal.pone.0149011.g002
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~62% and 54% of the total chlamydial proteome for EBs and RBs respectively. Our proteomic
analyses were not designed to capture specifically exported proteins and, by definition, inclu-
sion membrane proteins are excluded from this approach since we only sought to analyse two
discrete bacterial populations, and not the membranes that bounded them. Nevertheless, 4 well
characterized inclusion membrane and 7 candidate inclusion membrane proteins were
detected. In every case, these proteins were more abundant in purified RBs. Since the extensive
density gradient purification protocols (which are severely detrimental to the preservation of
fragile membrane structures) were used to purify EBs and RBs, we conclude that these inclu-
sion membrane proteins are synthesized de-novo and are ‘in transit’.
Overall proteome coverage compares very favorably with the most recent study where 54%
and 42% coverage of the predicted EB and RB proteome of C. trachomatis L2 was catalogued,
respectively [17]. Although we expected some similar biological observations to Saka et al.,
their experimental design was different and they cultured C. trachomatis using a different cell
line (Hela cells) to that in our study (BGMK), they also attempted to purify inclusion mem-
brane proteins and used a different infection strategy (multiplicity of infection).
Most abundant proteins
S2 Table summarizes the data for the 15 most abundant proteins in RBs, whilst S3 Table
shows the equivalent data for EBs. The dynamic expression range minimally spans three orders
of magnitude from 0.96 to 1,428 fmol on column. In keeping with previous results [28, 29], the
major outer membrane protein, MOMP, was found to be the most highly abundant component
in EBs and the second most abundant in RBs. The hitherto hypothetical gene product
CTL0847 was also amongst the most highly expressed components in C. trachomatis. The fact
that highly abundant uncharacterized proteins were not uncovered previously underscores the
generally poor correlation between mRNA and protein abundance data, as well as the power of
the MSE approach.
For EBs and RBs, protein abundance can also be expressed as estimates of molecules/bacterial
cell (S1, S2 and S3 Tables). Thus, MOMP is present at approximately 2700 copies per bacterial
cell, whilst proteins such as the conserved hypothetical protein CTL0455 and tetratricopeptide
repeat protein, CTL0052 were present at fewer than 15 copies per cell. Proteins in the second cat-
egory, that are also essential for cell viability may represent particularly attractive targets for anti-
microbial drugs as relatively few copies need to be inactivated in order to block growth.
The energy invested into making different classes of proteins
Comparison of the absolute quantification data for RBs and EBs suggests that protein levels
were generally lower in EBs although certain proteins, e.g. integration host factor (CTL0519),
acyl carrier protein (CTL0488) were present at higher levels. The absolute quantitation data
has permitted estimates of the energy invested in the synthesis of proteins belonging to differ-
ent functional categories. Our results indicate that C. trachomatis expends significant amounts
of energy into maintaining the translation machinery and synthesizing proteins associated
with cell envelope function, as well as hitherto hypothetical proteins (Fig 3). The majority of
cell envelope related commitment was concerned with the synthesis of MOMP. We speculate
that maintaining the translational components is critical during the initial stages of infection
and hence are accumulated and maintained in EBs in anticipation of this event.
Expression of cell wall enzymes in EBs and RBs
The presence of an essentially complete set of genes for peptidoglycan biosynthesis, together
with the penicillin sensitivity of C. trachomatis, strongly suggests that the pathogen has the
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capacity to build a partial cell wall and the existence of such a peptidoglycan structure was
recently proven using click chemistry [30]. Our UPLC-MSE analysis detected the majority of
enzymes involved in peptidoglycan synthesis which, in keeping with previous transcriptomic
and more limited proteomic studies [14, 31, 32], were generally only expressed in significant
amounts in the RB form (S2 Fig). The exception to this trend was muramidase, which showed
1.4-fold elevation in EBs. This suggests that peptidoglycan structures synthesized in the RB are
actively degraded as the pathogen switches to its extracellular infectious form. Consistent with
the proposed role of the cytoskeletal protein mreB (CTL0078) in cell division, we observed ele-
vated levels in the early RB.
Type III secretion
Since proteins exported from the cell are ‘lost’ to the pathogen they present a greater burden on
the bacterial cell, as their amino acids cannot be recycled. Thus evolution of the secreted pro-
teins and the apparatus to secrete them represents a critical step in intracellular adaptation.
Given that chlamydia only have a very limited ‘window’ to exploit the host eukaryotic cell, we
hypothesize that the process of evolution to an intracellular existence has ‘optimized’ the use
specific use of extracellular proteins so that function of the chlamydial TTSS is rapid and highly
efficient, especially in the early stage of infection.
The Chlamydia encode between 20 to 30 genes for structural proteins and chaperones of the
TTSS [33, 34]. Our study has provided quantitative data for 15 structural proteins (Table 1),
Fig 3. Estimated percentage energy investment in different functional classes of proteins for proteins present in 2+ EB replicates and/or 2+ RB
replicates. Blue, RB proteome; Red, EB proteome; Purple, proteins up-regulated in EB; Green, percentage of proteome in functional class.
doi:10.1371/journal.pone.0149011.g003
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4 chaperones and 25 effector proteins of the TTSS including CopD, CopB, CopN, Pkn5 and
CADD. The expression levels of the predicted structural TTSS proteins, with the exception of
SctW (CTL0344) showed reduced levels of expression in the late stage (48 h PI) of infection
and in some cases, were only present in RBs at 15 h PI. Collectively, these data suggest an
increased TTS capacity in RBs at 15 h PI that is reduced later in the developmental cycle, an
observation consistent with the reported expression of the TTS-specific genes mid-cycle [35]
and at a time when the intra-vacuolar environment is being heavily modified by predicted TTS
substrates [36]. Relatedly, the predicted effector proteins, including IncA, IncE, IncG, IncC,
and 7 additional predicted inclusion membrane proteins were also detected and, where quanti-
tative data was available, showed decreased levels in EBs, indicating their secretion. The excep-
tion to this trend was the multi-cargo effector chaperone Mcsc, which was equally abundant in
both RBs and EBs and the effector protein CADD (Chlamydia protein associating with death
domains, CTL0874), which was more abundant in EBs and has previously been shown to be
expressed late in the developmental cycle and to modulate host cell apoptosis [37].
Whereas we observe a reduced capacity later in the developmental cycle, Saka et al.,[17]
reported a marked absence of TTSS components in RB and proposed a reduced TTSS capacity,
or a limited number of active TTSS apparatus in RBs. Notably, the absence of the C-ring com-
ponents of the TTSS basal body, SctQ and the ATPase, SctN in RBs, led the authors to suggest
substitutes for these components in the RB form. By contrast, our data indicate higher expres-
sion levels of the TTSS components in RBs with reduced expression in EBs, a trend that is con-
sistent with the decrease of the TTS-like projections per bacterium, observed during the
transition from RB to EB. Additionally, the C-ring components, SctQ and SctN were expressed
at 162 ±68 and 91 ±11 molecules/cell in RBs, respectively, and 54 ±10 and 45 ±18 molecules/
cell in EBs, respectively. To validate our data in the TTSS we compared expression levels by
immunoblot of CT0847, a type III secretion structural protein associated with the needle tip
component from C. trachomatis L2 in purified EBs and RBs. CT0847 is equivalent to CT584 in
Table 1. Structural proteins of the Type III secretion apparatus identified.
Locus Protein RB EB Location
CTL0345 SctV/LcrD/CdsV 252±132 65±20 IM
CTL0344 SctW/LcrE/CopN 54±11 42±18 Secreted
CTL0038 SctN/CdsN 91±11 45±18 CP:MA
CTL0041 SctQ/CdsQ 162±68 54±10 IM
CTL0825 SctR/CdsR 32±16 ND IM
CTL0826 SctS/CdS ND ND IM
CTL0826 ScT/CdsT ND ND IM
CTL0036 SctU/CdsU 33±10 ND IM
CTL0043 SctC/CdsC 260±125 75±12 OM
CTL0033 SctD/CdsD 924±441 341±7 IM
CTL0035 SctF/CdsF ND ND Needle
CTL0822 SctJ/CdsJ 566±249 228±24 Link between IM & OM
CTL0824 SctL/CdsL 159±35 115±27 CP
CTL0841 CopB 73±8 31±5 HCM
CTL0842 CopD 134±21 76±12 HCM TL
CTL0238 LcrV 70±14 55±28 HCM TL
IM: inner membrane; OM: outer membrane; CP: cytoplasmic; MA: membrane associated; HCM: host cell
membrane; TL: translocon component. Nomenclature adapted from Beeckman and Vanrompay, 2010 [38]
doi:10.1371/journal.pone.0149011.t001
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urogenital C. trachomatis and Cpn0803 in C.pneumoniae, it is one of the most highly abundant
proteins (S1 Table). Our immunoblot data (S3 Fig) support our quantitative proteomics data
and show a nearly equal abundance of this TTSS protein in both forms. We postulate that the
expression of SctQ and SctN is ramped-up to pre-pack future EBs, and we observe expression
of these TTS components at 15 h PI. Nonetheless, our data does show the expression of TTSS
components in EBs, albeit at lower levels than RBs, supporting the hypothesis that EBs are pre-
loaded with TTSSs [33].
Energy metabolism
Until recently, the dogma has been that EBs are metabolically dormant. However, we identified
all the chlamydia-encoded enzymes for glycolysis, tricarboxylic acid cycle and pentose phos-
phate pathway in both RBs and EBs. This suggests that chlamydiae are capable of ATP synthe-
sis via glucose catabolism throughout their developmental cycle. Omsland et al. (2012) [18]
using axenic culture have shown that both EBs and RBs are able to perform de novo protein
synthesis and generate ATP. They also showed that EBs preferentially required glucose-
6-phosphate and RBs showed further enhanced activity in the presence of ATP. In keeping
with this, the quantitative measurements in our study indicate that these glucose metabolism
enzymes, including the ADP/ATP translocase, are at their most abundant in the RB form (15 h
PI), and show a general trend for decreased levels of expression in EBs (48 h PI). A summary of
the expression levels of these glycolytic enzymes is shown in Fig 4. Despite the higher levels of
these enzymes in RBs, the abundance of these enzymes in EBs is significant, confirming that
chlamydiae have the capability to generate ATP via substrate-level phosphorylation through-
out their developmental cycle, an observation that is consistent with previous RT-PCR results,
which showed maximal expression of the genes PK, GAPDH, PGK and ZWF in RBs [39]. We
have calculated to a first approximation, the functional categories where energy is expended in
synthesizing proteins. Since EBs are metabolically active and also maintain a protein transla-
tion capability, proteins required for extracellular survival or the initial stages of infection can
be synthesized on demand.
Gaps in the proteome coverage
The major region of variation between coding sequences of the different chlamydial strains
and species is the region termed the plasticity zone (PZ). This variant region is principally
attributed to the loss of the cytotoxin gene(s), which have almost entirely been deleted from C.
trachomatis L2 leaving two remnants CTL0420 and CTL0421 [40]; and 4 encoded phospholi-
pase genes, CTL0409, CTL0411, CTL0413 and CTL0414. However, although CTL0409 and
CTL0414 have acquired multiple frameshift mutations and deletions, CTL0411 and CTL0413
appear intact in UW-3 (serovar D), Har-13 (serovar A) and L2. Mapping of the identified pep-
tides from RBs and EBs to the L2 genome (Fig 2), there is a striking absence of peptides
detected across the PZ, although proteins encoded by the trpRBA operon, potentially linked
with genital and ocular tropism were detected [41]. This absence would be expected for the pre-
dicted pseudogenes (S4 Table) and validates their assignment to this category. However, the
clear and notable absence of peptides mapping to other predicted ‘functional’ genes able to
encode proteins, such as the phospholipase genes, CTL0411 and CTL0413, spanning this same
region, does raise the question whether these genes are expressed or whether they too are non-
coding either at the level of transcription or translation.
Of the proteins not identified in this study, of particular note are hypothetical proteins, or
proteins of unknown function, representing>10% of the predicted C. trachomatis L2 genome
(S4 Fig). By comparison the remaining unidentified proteins were fairly evenly distributed
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across the remaining 13 functional categories. Interestingly, in a previous study focused on
improving pseudogene assignment, using 11 genomes from 4 bacterial genera, the number of
pseudogenes ranged from 27 in Staphylococcus aureusMW2 to 337 in Yersinia pestis CO92.
Over half of these pseudogenes identified were previously annotated as ‘hypothetical’ [42].
Considering the high representation of ‘hypotheticals’ within this dataset, we speculate that
these could also represent unassigned pseudogenes; or are they characteristically atypical pre-
venting their detection; or are they simply not expressed under the conditions of measurement?
Whatever the reason for the gaps in the proteome coverage, it is clear that accurate prediction
of pseudogenes is required in defining our understanding of what represents a complete
proteome.
Concluding remarks
Proteome-wide determination of absolute protein quantities is a challenge of broad biological
importance. In this study, we have determined and compared the levels of hundreds of proteins
Fig 4. Representation of the glycolytic pathway inC. trachomatis L2 (A) and associated expression levels of each glycolytic enzyme from 15 to 48 h PI (B).
*There is no hexokinase homolog in theC. trachomatis L2 genome.
doi:10.1371/journal.pone.0149011.g004
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in the EB and earliest RB forms of C. trachomatis. Such data provides insights into the steady-
state levels of proteins and hence cellular priorities for protein synthesis. It also allows explora-
tion of structural, functional and genetic correlates of protein abundance (amino acid composi-
tion, pI, gene essentiality), and is an important prerequisite for predictive mathematical
modeling of cellular processes. These high quality data are reproducible, robust and reliable for
high abundance proteins. However, the subtleties of chlamydial gene regulation are likely to lie
within the proteins of low abundance (<10 copies per cell). In pathogenic microbes these are
of specific interest as they may be of use in the selection of targets for the development of new
antimicrobial agents. It is likely that there is a greater variation in the copy numbers of low
abundance proteins as feedback control of low concentrations is notoriously difficult, and eas-
ily leads to overshooting and random oscillations [43]. The availability of accurate quantitative
proteomics data, indicating levels of protein/enzymes in RBs and EBs is a fundamental
resource and will be invaluable for planning future experiments to manipulate the genome to
investigate gene regulation and function.
Supporting Information
S1 Fig. Comparison of the absolute protein abundance measurements obtained from the
analysis of two technical replicates of EBs (S1a) and RBs (S1b) from C. trachomatis L2
using 2D-LC-MSE. Protein abundance from replicate 1 and 2 are represented on a log2 scale.
R2 = correlation coefficient.
(ZIP)
S2 Fig. A schematic representation of the proposed chlamydial peptidoglycan biosynthesis
pathway and related genes. The precursor, UDP-MurNAc pentapeptide is synthesized in the
cytoplasm by six enzymes (MurA to Mur F). This precursor is subsequently transferred to the
lipid carrier undecaprenyl phosphate catalyzed by MraY to form the first membrane bound
intermediate, Lipid I. Catalysed by MurG, Lipid II is synthesized by the addition of UDP-Glc-
NAc to Lipid I, followed by translocation into the peptidoglycan structure. The table indicates
those peptidoglycan biosynthetic enzymes expressed in C. trachomatis L2.
(TIF)
S3 Fig. Immunoblot detection of the highly abundant proteins MOMP and the protein
encoded by CTL0847. SDS–PAGE (A) and western blot analyses (B and C) of gradient–puri-
fied EBs and RBs. EBs and RBs were loaded in the gel tracks as indicated. In panel B the
MOMP protein (~40kDa) was detected by monoclonal antibody 6Ciii and in panel C the pro-
tein encoded by CTL0847 was detected with a polyclonal mouse antiserum specific for this pro-
tein. The migration of the molecular weight markers are as indicated.
(TIF)
S4 Fig. C. trachomatis L2 proteins not yet identified in this study, distributed according to
functional category.
(TIF)
S1 Table. Main data table.
(XLSX)
S2 Table. 15 Most abundant proteins in RB.
(PDF)
S3 Table. 15 most abundant proteins in EB.
(PDF)
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S4 Table. Pseudogenes in C. trachomatis L2/434/Bu identified by whole genome compari-
son with C. trachomatis strains UW-3 (serovar D) and Har-13 (serovar A).
(PDF)
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